Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | ITGB3 | P05106 | 10/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | F2R | P25116 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2746849 | 0.96 | NAAA (0.57) | NAAAGAALMNAITGB3ITGA2B | |
| SCHEMBL2746605 | 0.92 | LMNA (0.56) | NAAALMNAITGB3ITGA2BBCHE | |
| SCHEMBL2747483 | 0.87 | ITGB3 (0.47) | LMNAITGB3ITGA2BF2R | |
| SCHEMBL2745501 | 0.81 | LMNA (0.50) | NAAAGAALMNAITGB3ITGA2B | |
| SCHEMBL30919787 | 0.81 | MEN1 (0.55) | NAAAGAALMNAITGB3ITGA2B | |
| SCHEMBL5540757 | 0.78 | LMNA (0.51) | NAAAGAALMNAITGB3ITGA2B | |
| SCHEMBL14400225 | 0.77 | BCHE (0.57) | NAAAGAALMNAITGB3ITGA2B | |
| SCHEMBL5542690 | 0.76 | ITGB3 (0.49) | GAALMNAITGB3ITGA2BF2R | |
| SCHEMBL14215418 | 0.76 | RAB9A (0.48) | GAALMNAITGB3ITGA2BF2R | |
| SCHEMBL2746619 | 0.76 | HSD17B10 (0.47) | NAAAGAALMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. | 2012-08-16 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1806342-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | CNR2, CNR1, HRH4 | NAAA 657/4885GAA 4010/4885LMNA 4280/4885 |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | NAAA 841/4885GAA 4580/4885LMNA 3604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.